[Skip to Content]
[Skip to Content Landing]
Article
February 1961

Recent Treatment Programs for Generalized Scleroderma

Author Affiliations

ROCHESTER, MINN.

Mayo Clinic and Mayo Foundation (Dr. Perry, Section of Dermatology). The Mayo Foundation, Rochester, Minn., is a part of the Graduate School of the University of Minnesota.

Arch Dermatol. 1961;83(2):300-304. doi:10.1001/archderm.1961.01580080130014
Abstract

Any discussion of the treatment of scleroderma should be prefaced with the remark that such treatment is most unsatisfactory under most circumstances. This general group of diseases is among the most difficult to treat and offers the greatest therapeutic challenge. The treatment of scleroderma has been characterized by an ever-changing spectrum of oral medication, injections, and surgical procedures.

The course of scleroderma is variable with periods of progression and remission despite supposedly definitive therapy. Except for the recent studies of Curtis and Jansen1 regarding the prognosis of localized scleroderma, little information is available on the course of untreated scleroderma. The enthusiasm for the particular therapy rarely has been assessed against the prognosis of the nontreated patient. It is with this knowledge in mind that we must evaluate some therapy currently in use.

Although in the past each form of scleroderma was considered a separate entity, today the various clinical

First Page Preview View Large
First page PDF preview
First page PDF preview
×